Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Driven by commercialization milestones for Keytruda SC (Keytruda Qlex) and an upfront payment from the AstraZeneca licensing agreement, ALTEOGEN achieved consolidated revenue of KRW 215.86B (+109.8% YoY) and operating profit of KRW 106.90B (+320.8% YoY) for FY2025.
📊 [Key Disclosure Details & Major Figures Summary]
- Type of Financial Statements: Consolidated (K-IFRS Standard)
- Fiscal Period: January 01, 2025 – December 31, 2025
- Financial Performance Details (Current FY vs. Prior FY):
- Revenue: KRW 215,858,918,957 (Approx. KRW 215.86B / +109.8% YoY, Change: +KRW 113.00B)
- Operating Profit: KRW 106,900,077,097 (Approx. KRW 106.90B / +320.8% YoY, Change: +KRW 81.50B)
- Profit Before Income Tax: KRW 162,736,332,654 (Approx. KRW 162.74B / +344.5% YoY)
- Net Profit: KRW 144,335,436,091 (Approx. KRW 144.34B / +137.8% YoY)
- Financial Position:
- Total Assets / Liabilities / Equity: KRW 697.90B / KRW 244.30B / KRW 453.61B (Capital Stock: KRW 26.75B)
- Primary Reasons for Changes:
- Revenue & Operating Profit: Increased revenue from Keytruda SC (US product name: Keytruda Qlex) commercialization milestones and an upfront payment from the AstraZeneca licensing agreement
- Profit Before Tax & Net Profit: Increase in non-operating income, including financial income
- Board Resolution Date: February 27, 2026 (2 Independent Directors attended, Auditor attended)
- Other Reference Matters: Figures are subject to change during the external audit and Annual General Meeting approval process
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of External Audit Report Receipt and AGM Approval of Financial Statements
This disclosure reports significant changes in annual revenue and profit structures prior to audit completion. Verifying whether the reported preliminary figures are confirmed without major adjustments in the upcoming external Audit Report and at the Annual General Meeting is essential because it allows investors to confirm the final, audited financial results. Detailed updates can be cross-checked in subsequent Audit Reports and periodic filings (Annual Reports).
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
